WE’LL SEE IF IT PANS OUT JACKIE THANK YOU VERY MUCH.
JACKIE DEANGELIS.
JACKIE DEANGELIS. LET’S GET THE READ FROM THE
FORMER HUMAN SERVICES
SECRETARY UNDER PRESIDENT TRUMP
HE JOINS US RIGHT NOW, SECRETARY
GOOD TO HAVE YOU.
>> THANK YOU.
NEIL: WE DON’T KNOW MUCH ABOUT
THIS PARTICULAR DRUG FROM GILEAD
BUT WE DO KNOW THAT OTHERS ARE
WORKING ON SIMILAR REMEDIES, I
COULD GO ON AND ON.
WHAT DO YOU MAKE OF WHAT YOU’RE
HEARING RIGHT NOW, SOMETIMES TO
GET TO FRUITION AND PAST
CLINICAL TRIALS IT COULD BE MANY
MONTHS UP TO A YEAR, NO WAY OF
KNOWING BUT WHAT DO YOU THINK?
>> WELL THIS IS FASCINATING
BECAUSE WHAT WE’RE WATCHING
RIGHT NOW IS THE RESEARCH AND
DEVELOPMENT OF NEW DRUG OR
DRUGS PLAYING OUT IN PUBLIC,
WHICH THE PUBLIC NEVER SEES.
THIS ISN’T AN EXACT SCIENCE.
IT GOES IN FITS AND STARTS AND I
THINK IT WILL GIVE FOLKS AN
OPPORTUNITY TO GAIN A MUCH
GREATER APPRECIATION OF THE
CHALLENGES THAT EXIST BUT
IT’S GOING TO BE A LONG PROCESS.
THERE WILL BE A LOT OF SETBACKS
AND FOLKS NEED TO BE PREPARED
FOR THAT.
FOR THAT. IT’S IMPORTANT NOT TO GET
FRUSTRATED AND THAT PATIENTS
IN COOPERATION IN ALL OF THIS IN
TERMS OF THE INFECTIOUS DISEASE
IS THE BUY WORD.
IT’S INCREDIBLY IMPORTANT AND
THAT’S NOT NECESSARILY THE
STRONG SUIT FOR A LOT OF
FOLKS.
FOLKS. NEIL: YOU KNOW, WHEN WE HEAR A
COMPANY LIKEMODERNA IS GETTING
$483 MILLION SEPARATELY FOR A
VIRUS VACCINE UNDER DEVELOPMENT,
HOW DOES THE GOVERNMENT MAKE
THOSE CALLS OR WHAT DOES IT SEE
FROM YOUR DAYS RUNNING, HOW
DO YOU SEE THIS LOOKS PROMISING,
THIS LOOKS LIKE IT MIGHT BE
WORTH SOME GOVERNMENT HELP TO
PUSH IT ALONG, HOW DO YOU DECIDE
THAT?
THAT? >> WELL AN INCREDIBLE AMOUNT OF
WORK GOES INTO THAT.
THAT MONEY IS COMING THROUGH THE
NIH, THE NATIONAL INSTITUTE
OF HEALTH AND SCIENTISTS ARE
LOOKING AT ALL OF THE STUDIES
GOING ON IN REALTIME ARE OVER
AND OVER AND OVER AND WHEN THEY
IDENTIFY SOMETHING THAT THEY
BELIEVE SHOWS SIGNIFICANT
PROMISE, THEN THAT’S WHERE THEY
PUT RESOURCES BECAUSE THOSE
RESOURCES ARE OBVIOUSLY
FINITE, AND IN MODERNA’S CASE,NI
H OBVIOUSLY SEES
SOMETHING THAT DEMONSTRATES TO
THEM THAT THERE MAY BE PROMISE
WITH A VACCINE THROUGH THAT
COMPANY AND CONSEQUENTLY THEY’RE
PUTTING GREATER RESOURCES,
RESOURCES THAT HAVE BEEN BROUGHT
TO BEAR ON THIS , ON COVID-19
ARE REALLY IMPORTANT FOR THE
AMERICAN PEOPLE TO
APPRECIATE BECAUSE WHAT THAT
MEANS IS THAT THERE’S GOING TO
BE A WHOLE LOT OF OPPORTUNITY TO
LOOK AT MORE AND MORE TREATMENT
OPTIONS AND VACCINE TRIALS THAT
NEED TO GO FORWARD, BECAUSE WE
DON’T GET TO THE END OF ALL OF
THIS UNTIL WE HAVE A HIGH
QUALITY TREATMENT AND/OR A
VACCINE THAT WILL MAKE IT SO
THAT FOLKS HAVE IMMUNITY TO IT,
SO AGAIN WHAT FOLKS ARE WATCHING
IS JUST THE NORMAL ROUTINE
PROCESS OF SCIENTIFIC
DEVELOPMENT, RESEARCH AND
DEVELOPMENT OF NEW MEDICATIONS,
NEW DRUGS COMING ONLINE, BUT
IT’S BEING PLAYED OUT IN PUBLIC,
IN A WAY THAT WE’VE NEVER SEEN
BEFORE.
BEFORE. NEIL: YOU KNOW WHAT’S
INTERESTING, LET’S SAY THAT YOU
COME UP WITH A VACCINE, TO YOUR
EARLIER POINTS AND INTERVIEWS AS
WELL BUT ONCE THAT HAPPENS
THEN YOU’VE GOT TO GET IT OUT TO
THE PUBLIC AND NOW IT CAN MASS
PRODUCE A VACCINE, IF THIS
PARTICULAR VACCINE IS
WORKING TO THE TUNE OF
600 MILLION DOSES COME NEXT YEAR
, BUT THAT MEANS THE VACCINE
IS OUT IN THIS PARTICULAR CASE,
BUT THEN YOU WAIT FOR THE
COMPANY OR COMPANIES
INVOLVED TO MASS PRODUCE IT SO
IT’S QUITE A MULTI-STAGE EVENT
ISN’T IT?
ISN’T IT? >> IT IS AND WE SEE THAT
FRANKLY PLAY OUT EVERY SINGLE
YEAR WITH THE NORMAL INFLUENZA,
THE FLU VACCINE, EVERY FALL
THERE’S A NEW VACCINE THAT COMES
ONLINE AND THE WORK THAT’S BEEN
DONE IN THE PRIOR-YEAR TO FIGURE
OUT WHAT’S THE BEST WAY TO
FORMULATE THAT VACCINE, AND THEN
THERE ARE MILLIONS AND MILLIONS
OF DOSES THAT ARE PRODUCED, SO
THAT WE CAN BE SAFER, AS IT
RELATES TO INFLUENZA WHICH AGAIN
CONTINUES TO BE A SEVERE
CHALLENGE FOR NOT JUST THE
UNITED STATES, BUT THE WORLD
EVERY SINGLE YEAR, SO VACCINE
COMPANIES, SANOFI AND OTHERS
CLEARLY HAVE THE CAPABILITY TO
PRODUCE HUNDREDS OF MILLIONS OF
DOSES OF VACCINES ONCE WE
DETERMINE THE ONE THAT IS MOST
EFFECTIVE FOR THE CORONAVIRUS,
WHICH I THINK WE WILL.
I THINK THAT WILL COME.
THIS IS NOT SOMETHING THAT THE
CORONAVIRUS IS NOT SOMETHING
THAT’S ABSOLUTELY NEW.
THIS IS A NEW KIND OF VIRUS BUT
IT’S NOT A NEW FAMILY OF VIRUSES
, BUT REMEMBER THAT WE
DON’T HAVE A VACCINE YET FOR THE
COMMON COLD WHICH IS A
CORONAVIRUS.
CORONAVIRUS. NEIL: RIGHT.
NEIL: RIGHT. >> SOME VIRUSES ALLOW
THEMSELVES THE OPPORTUNITY TO
MAKE A VACCINE AGAINST, SOME
DON’T AND THAT’S WHAT THIS
SCIENCE IS THAT WE’RE
WATCHING IN REALTIME PLAYED OUT
IN PUBLIC.
IN PUBLIC. NEIL: AS A DOCTOR AND GOING
BEYOND YOUR DAYS IN CONGRESS AND
RUNNING HEALTH AND HUMAN
SERVICES, DO YOU FEEL THAT IT’S
INEVITABLE EVEN THOUGH IT MIGHT
BE ECONOMICALLY IMPORTANT, THAT
WHEN WE GET BACK TO UNWINDING
SOME OF THESE STAY-AT-HOME
PROVISIONS THAT THERE WILL BE A
SPIKE IN CASES?
THAT THAT’S UNAVOIDABLE?
>> WELL I DON’T ONLY THINK IT’S
UNAVOIDABLE.
UNAVOIDABLE. IT’S ACTUALLY THE NATURAL COURSE
OF A NEW INFECTIOUS DISEASE.
THE FIRST STEP IN ALL OF THIS IS
MITIGATION WHICH IS THE PHYSICAL
DISTANCING THAT WE’RE UNDERGOING
AND THEN THE NEXT STEP IS THE
DETECTION, THE TESTING TO
MAKE CERTAIN THAT WE KNOW WHO
HAS IT SO THAT YOU CAN THEN
TRACE THAT AT THOSE INDIVIDUALS
AND THE PEOPLE THAT THEY CAME IN
CONTACT WITH AND THEN TREATMENT
AND THEN PREVENTION OF THE
VACCINE, BUT IN THAT PROCESS
, OBVIOUSLY, YOU’RE GOING
TO, THERE ARE GOING TO BE SOME
FALSE POSITIVES, SOME FALSE
NEGATIVES AND AGAIN THIS ISN’T
AN EXACT SCIENCE, AND SO THERE
WILL BE INDIVIDUALS WHO BELIEVE
THAT THEY HAVE IMMUNITY, WHO THE
TESTS HAVE SHOWN HAVE
IMMUNITY, THAT WILL LIKELY GET
INFECTED, AND THEN YOU’LL
HAVE ANOTHER POTENTIAL FOR
ANOTHER SPIKE, AND THAT’S
THE NORMAL COURSE FOR NEW
INFECTIOUS DISEASE, SO WOULD NOT
BE UNUSUAL IN FACT WE OFTEN
ANTICIPATE THAT AND AGAIN THAT’S
WHY I SAID PATIENTS AND
COOPERATION IS ABSOLUTELY THE
KEY BECAUSE THAT’S WHAT’S
REQUIRED OF A POPULATION IN
ORDER TO GET THROUGH A NEW
INFECTIOUS DISEASE.
INFECTIOUS DISEASE. NEIL: SECRETARY, THANK YOU VERY
VERY MUCH, GOOD CATCHING UP WITH
YOU AND LEARNING A FEW DETAILS
ABOUT HOW THIS WILL ROLLOUT WHEN